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Abstract
Background: Agitated or violent patients constitute 10% of all emergency psychiatric treatment.
Management guidelines, the preferred treatment of clinicians and clinical practice all differ.
Systematic reviews show that all relevant studies are small and none are likely to have adequate
power to show true differences between treatments. Worldwide, current treatment is not based
on evidence from randomised trials. In Brazil, the combination haloperidol-promethazine is
frequently used, but no studies involving this mix exist.
Methods: TREC-Rio (Tranquilização Rápida-Ensaio Clínico [Translation: Rapid Tranquillisation-
Clinical Trial]) will compare midazolam with haloperidol-promethazine mix for treatment of
agitated patients in emergency psychiatric rooms of Rio de Janeiro, Brazil. TREC-Rio is a
randomised, controlled, pragmatic and open study. Primary measure of outcome is tranquillisation
at 20 minutes but effects on other measures of morbidity will also be assessed.
TREC-Rio will involve the collaboration of as many health care professionals based in four
psychiatric emergency rooms of Rio as possible. Because the design of this trial does not
substantially complicate clinical management, and in several aspects simplifies it, the study can be
large, and treatments used in everyday practice can be evaluated.
Background
Agitated or violent patients constitute 10% of all emergen-
cy psychiatric treatment [16]. The majority of these people
have severe psychiatric illnesses such as schizophrenia, af-
fective disorder or substance abuse [16]. Less frequently,
organic illness or serious psychological stresses underlie
the aggression.
Guidelines recommend that patients should be 'verbally
tranquillised' for the doctor to proceed with a diagnostic
history, and undergo physical examination and laborato-
ry tests before starting any pharmacological treatment
[10]. A violent patient, however, may not allow this kind
of management and doctors and nurses have to work with
very limited background knowledge. Although some pa-
tients who are prone to violent episodes may be well
known to the psychiatric services, many represent a con-
siderable problem for the team faced with the challenge of
initiating treatment before any firm diagnosis is possible.
The psychiatric team has a responsibility to ensure the
safety of everyone involved.
Rapid and safe tranquillisation of aggressive/violent pa-
tients is sometimes unavoidable. Medication is given, of-
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making the patient less agitated and hostile. Drugs may be
given orally, intravenously (IV), or by injections into the
muscle (intramuscular/IM). With the acutely disturbed
person, oral medication is often not possible. Although
some psychiatric units prefer IV administration [7], its use
can present additional difficulties and risks. IV adminis-
tration may be problematic in aggressive and violent peo-
ple who are difficult to contain whilst a controlled
injection is given. IV administration may also cause cardi-
ac and respiratory problems not seen with intramuscular
injections [2,16] and is best employed where good medi-
cal support is readily available [7]. Finally, IM injections
can be easier to administer in the acute situation but the
onset of tranquillisation may be less swift and predictable
than with an IV injection.
Guidelines
Exactly which drug, or combination of drugs, is best to use
for the purpose of rapid tranquillisation of aggressive
mentally ill people is still a matter of debate. High profile
consensus guidelines do not give clear recommendations
(see Table 1).
Surveys of favoured treatments
The advice of these guidelines, however, may not fit with
the preferred treatment of clinicians. Groups of doctors in
the UK [7] and USA [4] have been asked to list their pre-
ferred pharmacological management of acutely aggressive
patients. Medical Directors in the USA frequently recom-
mended the use of the high potency antipsychotic, ha-
loperidol, combined with the benzodiazepine,
lorazepam. In 1996, a group of doctors in England pre-
ferred the use of chlorpromazine (Table 2).
Surveys of practice
Neither guidelines nor the management preferred by cli-
nicians may reflect real-world practice. Surveys undertak-
en in Emergency Rooms can shed some light on what is
actually being used for acutely disturbed people. Table 3
shows the results from two European studies undertaken
in general hospitals emergency rooms. In the UK [20], in-
travenous treatments were common and the doses em-
ployed high. In France [18], were aggression due to
intoxication was common, mostly loxapine IM was used.
As the European studies suggested that very different clin-
ical practices were being undertaken, and it is unclear how
these results reflect what is happening in Brazil, a survey
was designed and completed in March 2000 [13].
The Rio de Janeiro survey [13]
The county of Rio de Janeiro has about 5.8 m habitants
and four public hospitals are responsible for the care of
about 70% of the population (Hospital Phillippe Pinel,
Centro Psiquiátrico Rio de Janeiro, Centro Psiquiátrico
Pedro II and Hospital Jurandir Manfredini). The period of
the survey covered emergency consultations from Satur-
day 25th March 2000 to Friday 31st March 2000, inclu-
sive. The Emergency Room notes were inspected and
medical records sought for additional information on use
of emergency intramuscular sedation. As the main focus
of the survey was the management of people with psy-
chotic illness, whenever a primary diagnosis of substance
abuse was made, data were not recorded.
Table 3 includes the results of this work and sets it against
the European studies. In Hospital Jurandir Manfredini,
133 patients attended the Emergency Room in this period,
but data on medication used could not be collected and
subsequently are not presented in the table. During the
seven-day period in the three other Rio's hospitals 764 pa-
tients attended at the emergency rooms and at least 74
(9.7%) received emergency sedative intramuscular drugs.
Intravenous sedation was not used and no patient re-
ceived extra parenteral doses for the same episode. Com-
plications or adverse events due to the use of medication,
as well as the use of physical restraints, were not recorded,
but it is likely that some people were subject to four-point
restraint, as it is accepted practice in these hospitals. A ha-
loperidol-promethazine mix was the most popular com-
bination and was used in over 80% of these emergencies,
alone or in combination with other drugs.
Systematic reviews
Several systematic reviews have been undertaken to inves-
tigate whether the use of any particular drug regimen is
Table 1: Guidelines and their recommendations for emergency management
Date Source Guideline Pharmacological recommendation
1999 USA Expert Consensus Guidelines Series [10] Give conventional antipsychotics for patients who require 
IM medications
1998 UK Royal College of Psychiatrists [22] Use rapid acting antipsychotics oral, IM, IV or rapid acting 
benzodiazepines such as lorazepamPage 2 of 12
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objective appraisals of randomised trials, incorporate ex-
tensive searches and, where possible, meta-analyses.
In the field of acute sedation, zuclopenthixol acetate
(Clopixol Acuphase) has been subject to the largest evalu-
ation within randomised trials (Table 4). It is a relatively
expensive treatment, widely advertised to be of value for
management of acute disturbance, and is used in Europe.
Although the total number of people randomised into zu-
clopenthixol acetate trials is greater than for other com-
pounds used for rapid tranquillisation, data are not
decisive. None of the results is statistically significant in
favour of either approach. Data are poorly reported and
clinically relevant results rare. There are not enough data
to support its use over other, less expensive, treatments.
Although haloperidol is the most frequently recommend-
ed drug to manage acute aggressive behavior, only 40 peo-
ple were randomised within a single trial comparing
haloperidol (IV) to placebo for acutely disturbed psychi-
atric patients (Table 5). Data suggest that haloperidol aids
improvement.
No trials have been identified investigating the value of
the haloperidol-promethazine mix.
Benzodiazepines are also indicated by key guidelines, but
there are little data on the comparison of these drugs ver-
sus placebo for the acute management of disturbed peo-
ple (Table 6). No clinically useful conclusions can be
drawn from these data.
Although two studies were found comparing typical an-
tipsychotics and benzodiazepines to placebo, in the great
majority of the emergency situations it is not desirable,
safe or ethical to provide no treatment.
When comparing benzodiazepines with typical antipsy-
chotics, data suggest that benzodiazepines are more likely
to produce 'improvement' by 1.5 hours, but patients may
also be at greater risk of needing additional injections (Ta-
ble 7). More patients given haloperidol are asleep by three
hours than those allocated to benzodiazepines. No trials
present useful data on the use of midazolam; only one tri-
al exists (n = 15)[27] and it is not possible to analyse these
data.
Table 2: Pharmacological treatments and outcomes favoured by clinicians
Study Favoured regimen Number of Doctors
USA 1999 [4] Haloperidol + lorazepam +/- benztropine 11 (55%)
Droperidol 4 (20%)
Benzodizepine (unspecified) alone 3 (15%)
Droperidol + lorazepam + diphenhydramine 1 (5%)
Haloperidol + benztropine 1 (5%)
Use of physical restraints
Common 14 (70%)
Usually not used 6 (30%)
Route of administration
Preferred IM or IV 14 (70%)
Preferred IM 3 (15%)
Unknown 3 (15%)
UK 1994 [7] Chlorpromazine 14 (50%)
Haloperidol 8 (29%)
Haloperidol + chlorpromazine 2 (7%)
Droperidol 1 (4%)
'Neuroleptic' 1 (4%)
Haloperidol + diazepam 1 (4%)
Haloeridol + lorazepam 1 (4%)
Desired end point
Sedated but mobile 12 (43%)
Not sedated but calm 9 (32%)
Asleep 7 (25%)
Route of administration
Preferred IM 26 (93%)
Preferred IV 2 (7%)Page 3 of 12
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Incidents Physical 
restraint
IV:IM Drug of choice Frequency of use mean dose in 
mg (range)
Second 
injection
Complications / 
comments
UK 1997 
[20]
3.3 / week / 
100,000 catchment 
area population ~5 
people per week
64% 
(nurses)
1:1 Diazepam Most frequent 27 (10–80) 1 hypotention
Haloperidol (exact data not 
presented)
22 (10–60) 26% 1 cardiorespira-
tory arrest (60 
mg haloperidol 
+ 80 mg DZ)
Chlorpromazine 162 (50–400) 1 tachycardia, 1 
hypotention
Droperidol 14 (10–20)
Paraldehyde 1 respiratory 
distress
Amytal
Lorazepam
Nitrazepam Least frequent
France 1999 
[18]
5.6 / 1000 contacts 86% 
(nurses)
0:80 Loxapine 80% 200 mg 2 with acute 
dystonia
Droperidol 5%
Chlorazepate 5%
Cyamemazine < 2% 6% Mostly people 
with substance 
abuse
Diazepam
Sultopride
Meprobamate
Brazil 2000 
[13]
2.1 / week / 
100,000 catchment 
area population 
~74 people per 
week
Majority 
(restraints 
and nurses)
0:74 Haloperidol + 
promethazine
61% 5 (2.5–10) + 50 
(25–100)
0%
Haloperidol + 
Promethazine + 
Diazepam
15% 5 (2.5–10) + 50 
(25–100) + 10
Diazepam 9% 10
Haloperidol + 
Promethazine + 
Chlorpromazine
7% 5 + 50 + 25
Chlorpromazine 
+ Diazepam + 
Promethazine
1% 25 + 10
Chlorpromazine 
+ Promethanzine
1% 25 + 50
Chlorpromazine 1% 25
Diazepam + Pro-
methazine
1% 10 + 5
Haloperidol + 
Diazepam
1% 5 + 10
Promethazine 1% 50Page 4 of 12
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Main outcomes Zu. Ac. Control RR (95% CI)
Not sedated by 2 hours 6/20 10/20 0.6 (0.3–1.3)
Needing another injection 12/20 8/20 1.5 (0.8–2.9)
Mental state: no improvement – by 36 hours 11/103 11/85 0.86 (0.4–1.9)
Leaving the study early 6/192 7/166 0.75 (0.3–2.3)
Table 5: Haloperidol versus placebo – 1 trial, 40 participants [15]
Main outcomes Hal'dol Placebo RR (95% CI)
Not improved by 2 hours 2/29 4/11 0.19 (0.04–0.9)
Needing another injection Majority in both groups
Mental state: asleep – by 2 hours 1/29 0/11 -
Leaving the study early 0/29 0/11 -
Adverse effects: needing antiparkinsonian 
medication
6/29 0/11 -
Table 6: Benzodiazepines versus placebo – 1 trial, 12 participants
Main outcomes Benz. Placebo RR (95% CI)
Not improved 1/6 5/6 0.2 (0.03–1.2)
Leaving the study early 0/6 0/6 -
Table 7: Benzodiazepines versus typical antipsychotics – 7 trials, 206 participants
Main outcomes Benz. Control RR (95% CI)
Not improved by 90 minutes 20/72 32/75 0.64 (0.4–0.98)
Needing another injection 24/31 31/35 0.66 (0.42–1.02)
Mental state: asleep – by 3 hours 31/74 21/74 1.6 (0.99–2.5)
Leaving the study early 14/101 16/105 0.87 (0.5–1.5)
Adverse effects: needing antiparkinsonian medication 4/31 9/35 0.50 (0.2–1.5)
Table 8: Benzodiazepine-haloperidol mix versus haloperidol alone – 3 trials, 96 participants
Main outcomes B-H mix Hal'dol RR (95% CI)
Not improved by 90 minutes 8/32 13/35 0.67 (0.3–1.4)
Needing another injection 27/32 31/35 0.95 (0.8–1.2)
Mental state: asleep – by 3 hours 20/32 11/35 2.0 (1.1–3.5)
Leaving the study early 0/49 0/47 -
Adverse effects: needing antiparkinsonian medication 3/32 9/35 0.36 (0.1–1.2)Page 5 of 12
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the value of a benzodiazepine-haloperidol mix for acutely
disturbed people (Table 8). The combination, largely with
lorazepam, is no better than haloperidol for all the out-
comes measured, except for 'being asleep by three hours',
which favours the benzodiazepine-haloperidol mix.
Setting
Eighty percent of people across the world live in low or
middle income countries and approximately 1–2% of
people suffer from severe mental illnesses [14]. There is
no evidence that psychiatric emergencies are less prevalent
in these countries, therefore, most episodes of aggression
for severely mentally ill people take place in the low or
middle income countries.
Although new preparations of atypical antipsychotic
drugs may be made available for use in the acute emergen-
cy, these are unlikely to affect the care of the majority of
people in need of tranquillisation. Typical antipsychotics
or benzodiazepines are relatively inexpensive, accessible
interventions for people right across the world. As these
treatments are prevalent in many countries, it is important
that a definitive study is undertaken to fully investigate
and understand their relative advantages and drawbacks.
From the systematic reviews listed above, it can be seen
that all pharmacological treatments of the psychiatric
emergency have been inadequately investigated.
The TREC-Rio study was designed in collaboration with
those working in a busy Brazilian psychiatric care setting.
The great majority of clinical trials are explanatory; they
are small, short, evaluate rigid care regimens, measure
outcomes in ways that are of little clinical value and are
difficult to relate to everyday practice.[24] Pragmatic tri-
als, on the other hand, evaluate care that can be used in
everyday practice and measure outcomes that are of gen-
eral concern [12]
Size
Two main factors determine the number of people who
should be recruited to in order for the trial to provide clear
answers. They are the frequency of the investigated event
and the size of the effect of treatment. It is important to
avoid results that are erroneous. The probability of pro-
ducing so called 'false-positive' results (type I error – α)
and 'false-negative' findings (type II error – β) is mini-
mised by having adequate sample size. The aim of TREC-
Rio is to investigate whether people do better if they get
haloperidol-promethazine or midazolam. The main out-
come to monitor in the TREC-Rio trial is the proportion
of patients who are tranquillised at 20 minutes in each
group.
In such a stressful situation, even a small advantage for an
intervention could represent a worthwhile benefit and so,
TREC-Rio has been planned so that even a 15% difference
in the proportion of tranquillised patients within the 20
minutes could be detected. TREC-Rio expects to involve
300 patients in a six-month period. A sample size of 300
people would have at least a 75% chance (1 – β error or
power) of detecting an absolute difference of 15% be-
tween the proportion of tranquillised patients in each
group, at 5% level of significance (α error) (Table 9).
Ethical considerations
The Helsinki Declaration [26], the European Directive on
Clinical Trials [9], and the Nuffield Council documents
on bioethics [19] state that trials in non-consenting pa-
tients are permitted on two conditions: i. no other context
exists in which to answer the question; and ii. all trial par-
ticipants get clear therapeutic benefit from whichever arm
they are randomised to.
Aggressive patients in a situation of psychiatric emergency
are not able to give consent for their participation in a
study. Drugs are usually given against the will of the pa-
tient. So, in the same way that doctors are responsible for
the choice of a treatment, they take responsibility for the
recruitment of a patient into the study.
However, TREC-Rio will not involve administering an in-
active compound to those who clearly need sedation/tran-
quillisation. Both treatments can calm the patient and
Table 9: Sample size needed to detect an absolute difference of 15% in the proportion of tranquillised patients (α = 5%, power = 80%).
Haloperidol + promethazine (% tranquilised) Midazolam (% tranquilised) N
5 20 152
10 25 200
15 30 242
20 35 276
25 40 304
30 45 326
35 50 340Page 6 of 12
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tain is the speed for the onset of action, the duration of the
effects and the different kinds of adverse reactions. TREC-
Rio will answer clinical questions to help the care of these
people be more informed. TREC-Rio will also produce
widely applicable findings, so that the treatment of people
beyond Rio de Janeiro should also be safer.
TREC-Rio has been approved by the ethics committees of
institutions in charge of research and local ethics commit-
tees of each hospital involved.
A patient/carer information leaflet about TREC-Rio is
available for all for whom a TREC-Rio box is opened. Car-
ers will always be free to decide that their relative should
not be entered. Not being involved in TREC-Rio will not
affect the person's standard of care.
Methods
The TREC-Rio study is a pragmatic study; it is randomised,
controlled and open. The protocol is summarised in Fig-
ure 1 and a Consort diagram is provided in Figure 2.
TREC-Rio is designed to fit into everyday practice
For the trialists to be able to detect important differences
between the treatments, it will be necessary to treat hun-
dreds of patients and this will only be possible if many
professionals collaborate in each centre involved. The
TREC-Rio trial is designed to not interfere with the routine
care of people in participating centres. The process of ran-
domisation is very similar to the normal procedure of be-
ginning the treatment and the eligibility criteria are
simple. Drugs will be provided in emergency sealed boxes.
Data collection will be limited to the minimum necessary,
and will involve little more than extraction of routine in-
formation by a person designated to spend time on the
TREC-Rio trial. It is not envisaged that busy doctors and
nurses will be spending time filling out complicated
forms and all trial materials. The interventions will be
supplied in a TREC-box that will be opened in the emer-
gency situation.
Randomisation
A fundamental step in such a trial is the randomisation;
the distribution of the treatments in a way that is not a
function of a clinical decision, but of pure chance. Ran-
domisation will be undertaken in the UK. Microsoft Excel
'RAND' function will be used to choose even numbered
block sizes less than ten. Again using this function, the or-
der of use of these block sizes will be randomised. Which
drug regimen was represented by which number within
the block was then selected, again at random. Finally a ta-
ble of random numbers will be used to randomise within
the blocks. Tables of TREC-box number by contents will
be constructed and will be supplied to a Brazilian col-
league. The tables will list the contents of the boxes in
groups of ten, not disclosing the block sizes used. The Bra-
zilian colleague, always working independently of the
TREC-Rio team, will ensure that the correct drugs are in
the TREC-box before it is sealed. Concealment of alloca-
tion will be ensured by not disclosing the randomly varied
block sizes to the colleagues packing the boxes, the supply
of tables to those colleagues that gives no suggestion that
blocks are even being employed, the independence of
those packing the boxes from the other researchers or the
clinicians, and the identical nature of the packed boxes.
These easy-to-use boxes will be constructed of cardboard,
identical and consecutively numbered. The final check to
ensure that nothing has gone wrong with the randomisa-
tion will be by the principal investigator filling in a form
for each block of ten opened boxes. She will record which
intervention was in the box and these data will be re-
turned to the UK so that any inconsistencies can quickly
become known.
TREC-Rio is blinded for the initial ratings only
Because the TREC-Rio study evaluates care in the emer-
gency situation, it is imperative that the doctors and nurs-
es know which intervention is being given. The study is
Figure 1
Protocol summary
Protocol summary
The TREC study is a large simple randomized trial designed to identify the best 
pharmacological treatment for managing agitated or aggressive people in the psychiatric 
emergency situation in Rio de Janeiro. It is designed to involve little or no complication to 
normal practice and to evaluate treatments readily used locally.
• Patient is needing acute intramuscular sedation 
because of disturbed and dangerous behavior and
• Clinician is uncertain about the benefits and risks of 
haloperidol plus promethazine versus midazolam
• The clinician believes that one treatment represents an 
additional risk for the patient
• Treatment is allocated using opening of consecutive TREC
boxes stored in the emergency drug cupboard. The box 
contains:
− The treatment
− One syringe, one needle, two swabs, one plaster
− TREC Forms to be filled out by the attending doctor/nurse
− TREC stickers for the patient's notes 
• Either
− haloperidol (2 X 5mg ampules) + promethazine (1 X 
50mg ampules)
or
− midazolam (1 X 15mg ampule)
• One or other supplied in the TREC box.
• All doses are at the discretion of the doctor
• All people for whom a pack is opened will be followed up by 
the TREC study co-ordinators
• Data will be extracted from the notes on clinical state, 
hospital status, sedation, use of additional medications and 
adverse reactions.
ELIGIBLE IF
EXCLUDE IF
TRIAL ENTRY
TREATMENT 
FOLLOW-UPPage 7 of 12
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opened. Therefore, it is crucial that the evaluation of the se-
verity of a person's disturbance and the first impression on the
possible cause for the disturbed behavior are recorded before this
box is opened. Once the box is opened, doctors and nurses
will have knowledge of the drug to be used. It is perfectly
feasible that the knowledge that one drug has been given
will influence the care beyond the actual effects of the
medication. Keeping the study open is not only practical
in the emergency situation, but also desirable as the eval-
uation of care being undertaken is as near real-world cir-
cumstances as is possible.
Participants
Aggressive/violent patients who arrive at the emergency
services of the public psychiatric hospitals of Rio de Janei-
ro-Brazil can be recruited for TREC-Rio.
Patients are eligible for trial entry if:
It is clear that they need acute intramuscular sedation be-
cause of agitation and disturbed and dangerous behaviour
and
The clinician is uncertain about the benefits and risks of
the comparator medications.
For the purposes of this trial, people are considered to be
agitated if uncontrollably and severely restless so as to
cause concern for safety in carer, or aggressive if they
present with threatening verbal behaviour, physical ag-
gression against objects, self-aggression or physical aggres-
sion against other people.
People are not eligible for trial entry if:
The clinician believes that one treatment represents an ad-
ditional risk for the patient.
Interventions
Placebo controlled studies in this area are difficult to jus-
tify (see section on ethics). TREC-Rio will evaluate the ex-
isting care in the health services of Rio de Janeiro and this
care involves the use of medication that is considered
both safe and effective. Currently, this protocol includes a
comparison of an intramuscular haloperidol-promethaz-
ine mix with an intramuscular rapid acting benzodi-
azepine, midazolam. In the future, other centers may wish
Figure 2
CONSORT DIAGRAM for TREC-Rio
For primary outcome - 20 minutes
For 24 hours outcome 
For 14 days outcome 
For primary outcome - 20 minutes
For 24 hours outcome 
For 14 days outcome
Analyse - intention to treat Analyse - intention to treat
Randomise
Assessed for eligibility by doctors 
working in TREC-Rio
Allocate to midazolamAllocate to haloperidol + promethazine
Not meeting inclusion criteria 
Carers refuse to participatePage 8 of 12
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azepine mix with lorazepam or zuclopenthixol acetate.
The haloperideol-promethazine mix is an obvious choice
as standard treatment for TREC-Rio. A pragmatic ran-
domised trial should not substantially interfere with rou-
tine practice and, in Brazil, this combination was given to
61% of patients needing sedation in the public psychiatric
rooms in Rio de Janeiro [13]. It is perceived as effective,
safe, and with adverse effects that are readily recognised by
both medical and nursing staff. It is easy to administer by
intra-muscular injection and has never been evaluated
within a randomised control trial. Haloperidol and pro-
methazine are both included in WHO's Model List of Es-
sential Drugs [25].
The comparison intervention in TREC-Rio is a rapidly act-
ing intramuscular benzodiazepine. Only lorazepam and
midazolam are indicated for IM use, as all other benzodi-
azepines are slowly and erratically absorbed by this meth-
od. Lorazepam is not available for IM use in Brazil,
however, midazolam is widely used in Brazil as premedi-
cation prior to surgical procedures in general emergency
rooms and its use for the management of acutely dis-
turbed people is being reported. The use of midazolam for
rapid tranquillisation in psychiatry has not been subject
to rigorous evaluation within a large and well-designed
randomised controlled trial.
All drugs, haloperidol, promethazine and midazolam are
included in Rio de Janeiro's list of essential drugs.
Haloperidol – risks and benefits
Haloperidol is a highly potent, widely used, neuroleptic
that is indicated to help promote adequate levels of tran-
quillisation when administered IM. Doses used are usual-
ly 5–10 mg and its onset of action is by 60–90 minutes.
The half-life of haloperidol varies between 13 and 40
hours, although effects may occur even two days after ad-
ministration. Adverse effects include akathisia (manifest-
ed as restlessness) in 20% and acute dystonic reactions
(rigid muscles and involuntary movements) for about 2%
of patients. Neuroleptic malignant syndrome (hypother-
mia, rigid muscles and alteration in the level of conscious-
ness developing 24–72 hours after administration) is an
idiosyncratic serious reaction occurring in 0.02–3.2% of
people [23]. Akathisia and acute dystonia are usually
treated with the administration of antimuscarinic agents,
although the optimal management of neuroleptic malig-
nant syndrome is unclear. despite these adverse effects,
which may happen even after a single injection, haloperi-
dol is the elected treatment, widely available and used in
the emergency situations.
Promethazine – risks and benefits
Promethazine is an antihistamine combined as an IM in-
jection with haloperidol for the management of acutely
disturbed people in both Brazil and India. The rational for
this combination lies in the main sedative effects of pro-
methazine and its antimuscarinic properties. Doses are
usually between 25–50 mg but, as adjunctive sedative for
emergency use, may reach 100 mg IM [23]. The onset of
action is about 1–2 hours after intramuscular administra-
tion and half-life is 5–14 hours. The main adverse reac-
tions of promethazine are gastrointestinal disturbances,
dry mouth and blurred vision. Paradoxical reactions such
as CNS stimulation and extrapyramidal symptoms have
also been reported. Overdose may lead to coma and con-
vulsions, progressing to respiratory failure or possibly car-
diovascular collapse.
Midazolam – risks and benefits
Doses of midazolam for IM sedation varies between 3–10
mg, depending on clinical condition of the patient and
previous exposure to other drugs. The onset of action is
rapid, and occurs in 15–30 minutes after IM administra-
tion. Midazolam's half-life is 2–3 hours, the duration of
action being generally up to 120 minutes. Few adverse ef-
fects are associated with IM use of midazolam. Amnesia
for the incident is likely to occur. Respiratory depression
and paradoxical reactions are only rarely associated with
IV use of the drug but with intramuscular administration
important changes in respiratory function have not been
observed. IM midazolam, however, can cause confusion
in about 0.3% of people. Flumazenil, a benzodiazepine
antagonist, can be used to reverse the sedation induced by
midazolam [23]. Flumazenil, a benzodiazepine antago-
nist, can be used to reverse the central effects induced by
midazolam. The initial dose is 200 µ g given intravenously
in 30 seconds, but additional doses may be needed, up to
3 mg. The onset of action occurs a few minutes after IV in-
jection and can last up to 3 hours. The half-life is about 50
minutes. The adverse effects to flumazenil resemble those
of withdrawal symptoms to benzodiazepines (nausea,
headache, dizziness, blurred vision). Flumazenil should
not be used in the presence of tryciclic intoxication or for
patients who have used benzodiazepines for seizures for a
long time.
Procedures
All trial materials, and guidelines for their use, are provid-
ed in the TREC-Rio folder supplied by the co-ordinating
centre. What follows here is a brief summary of all of trial
procedures.
Whenever possible, carers accompanying the disturbed
person should have an opportunity to see the information
leaflet (Appendix 1, see Additional file 1) before randomi-Page 9 of 12
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tem. Identical sealed treatment packs are provided.
As soon as the person enters the study, the clinician com-
pletes the trial entry form on the top of the next consecutive
pack (Appendix 2, see Additional file 1). This must be
completed before the treatment pack is opened. It records
brief baseline details about the person and the number of
the treatment pack. The treatment packs must be used in
order in which they are removed, the lowest number first.
Once the trial entry form has been completed the person
is in the trial, even if the doctor changes his/her manage-
ment and the treatment pack is not opened.
Trial packs
As soon as the person has been allocated a treatment pack,
the pack is opened and the trial treatment inside given.
Each pack contains:
1 × ampoule of midazolam 15 mg
1 × syringe
1 × needle
2 × swabs
1 × TREC-Rio follow-up form (Appendix 3, see Additional
file 1)
2 × TREC-Rio stickers for the drug prescription form and
medical notes
or
2 × ampoules of haloperidol 5 mg
1 × ampoule of promethazine 50 mg
1 × syringe
1 × needle
2 × swabs
1 × TREC-Rio follow-up forms (Appendix 3, see Addition-
al file 1)
2 × TREC-Rio stickers for the drug prescription form and
medical notes
All doses used are at the discretion of the attending clinician.
Ampoules will be clearly labelled and the clinician will be
in no doubt as regards the treatment being given. If the
contents of a trial pack are destroyed, or unfit for use, the
person should not be randomised a second time and the
equivalent material should be obtained from the usual
hospital supplies.
In the event of continuing aggression despite the TREC-
Rio medication, ongoing emergency management would
be up to the discretion of the clinicians. Another pack is
not opened and the doctor is free to use any standard in-
terventions.
Toxicity and serious unexpected events
After trial entry, clinical events are recorded, as usual, in
the patients' notes. Complications and adverse events
should be managed as usual. A serious unexpected event
form (Appendix 5, see Additional file 1) is provided, and
will be sent to the TREC-Rio Co-ordinator as soon it is
completed.
Outcome and follow-up
It is crucial that follow-up is complete and accurate for
everyone entered into the study. As a pragmatic study,
causing minimal interference with routine care, TREC will
not employ any rating scale outcomes. It is likely that
completion of scales would be inaccurate, and incom-
plete, validity and reliability would be in question, and
clinical utility problematic. The main outcome of TREC-
Rio is tranquillisation by 20 minutes. This primary out-
come was requested by the nursing and medical staff of
the relevant hospitals. By asking the relevant clinical staff
to select the primary outcome for TREC-Rio we hoped to
ensure maximum compliance with the trial protocol.
Therefore, upon injection of the patient, a timer is started,
and this rings at 20 minutes and then again at 40, 60 and
120 minutes. At each period the attending nurse rates
whether the person is tranquil, asleep, has shown adverse
effects or needs additional treatment (see Appendix 2, see
Additional file 1). This attending nurse is not blinded. The
person is considered tranquillised when they are felt to be
calm and peaceful, but not asleep. They should not be ag-
itated or restless, nor displaying threatening verbal behav-
iour, physical aggression against objects, self-aggression
or physical aggression to other people. Blinding this rater
for every participant would have added additional com-
plexity to the study that would have made the trial much
less acceptable to the emergency room staff. More impor-
tantly, it would have completely changed the emphasis of
TREC-Rio. We are interested in evaluating the real-world
practice of giving two different drug regimens in the psy-
chiatric emergency setting. In the real world situation
health care professionals know what treatment is being
given. In addition, for 10% of participants an additional
rater, blind to allocated treatment, will, unknown to the
health professionals looking after the patient, time the pe-
riod between injection and tranquillisation and / or sleepPage 10 of 12
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follow up form (see Appendix 4, see Additional file 1).
Additional data are then recorded at 24 hours and finally
at two weeks (see Appendix 6, see Additional file 1). All
data is extracted from routine notes. If the person is trans-
ferred to another hospital, the co-ordinating centre will
contact every hospital to find out further details on what
happened after transfer.
Data collection, entry and analysis
All data for TREC-Rio will be collated from the TREC-box
forms and routine notes of each emergency room or ward
(see Appendix 6, see Additional file 1). These data will be
entered by the principal investigator into especially creat-
ed forms in Epi-Info v 6.0 [5].
Analysis will take place within this package and SPSS [21].
Dummy tables for this analysis are prepared before re-
cruitment of the first patient (see Appendix 7, see Addi-
tional file 1). All analysis will be based on groups as
randomly allocated; this will be an intention-to-treat anal-
ysis. For the principal comparisons statistical significance
will be taken at a 5% level and for subsidiary comparisons
at the 1% level, to minimise the impact of multiple com-
parisons. Relative risk, risk difference, number needed to
treat and respective 95% confidence intervals will be esti-
mated for tranquillisation by 20, 40 and 60 minutes.
For the continuous outcome mean difference will be as-
sessed. As in most experiments, this study carried out a
randomisation of a non random sample instead of a ran-
dom sampling of a specific population. In order to be co-
herent with the adopted design, the statistical significance
of the means difference will be evaluated by a randomisa-
tion model (not a population model), and a design-based
permutation test will be used instead of an approximate
test to preserve the type I error rate [3,17]. Permutation
test will be performed using StatXact 3.0 for Windows [8].
For a subgroup of 10% of patients, quality of data on time
to tranquillisation will be evaluated by two independent
observers. The agreement of this measurement will be as-
sessed using Kappa statistics.
Trial organisation
The TREC-Rio Co-ordinating Group: The co-ordinating
centre of the Rio de Janeiro arm is based at Fundação Os-
valdo Cruz, Rio de Janeiro, Brazil. The Co-ordinating
Group has overall responsibility for the design of the pro-
posed trial and is responsible for all aspects of day to day
trial administration. The Co-ordinating team is also re-
sponsible for preparing reports for the steering commit-
tee. Membership: Gisele Huf, Evandro SF Coutinho, Clive
E Adams.
The TREC-Rio Steering Committee: The overall progress of
the trial, adherence to protocol, patient safety and the
consideration of new information will be monitored by a
scientific and administrative steering committee. At the
end of the proposed study period, the Steering Committee
will consider the extension of the study, to allow the de-
tection of other important effects. The membership of this
committee is: Dr. Marco Antônio Brasil (chair), Dr. Gisele
Huf, Dr. Evandro Coutinho, Prof. Clive Adams, Dr. Hugo
Marques Fagundes Jr., Dr. José Ramón R. A. Lopez, Dr.
Maurício Lima, Dr. Mário Barreira Campos, Dr. Suely Ro-
zenfeld and Rosaura Maria Braz.
Data monitoring
Should recruitment to TREC-Rio be slow (take more than
one year) or very swift (more than 300 in the expected six
month recruitment period), an independent data moni-
toring committee (DMC) will, in confidence, monitor re-
sults. Should recruitment to the TREC-Rio be slow or go
beyond 300, interim results will be supplied, in strict con-
fidence to the chair of DMC as frequently as requested.
Meetings of the committee will be arranged periodically
as considered appropriate by the chair of the committee.
In the light of the interim data, and of any other evidence
or advice they wish to seek, the data monitoring commit-
tee will inform the chair of the steering committee if, in
their view: i. there is proof beyond reasonable doubt that
for any particular group or subgroup treatment with one
or other regiment is clearly indicated or contraindicated
or: ii. it is evident that no clear outcome will be obtained.
Proof beyond reasonable doubt may be taken as the dif-
ference of at least three standard deviations and at least
one of the primary outcomes.
The data monitoring committee may communicate cer-
tain interim analysis to the steering committee or suggest
certain protocol changes, but the steering committee will
remain responsible for deciding which changes to adopt.
The membership of this committee is: Claudio Jose
Struchiner (chair), Luiz B. Camacho, Jair de Jesus Mari.
Funding
No participating centre will directly receive funds for in-
volvement in TREC-Rio. By design, funding for the overall
project is minimal. All funding is intramural and everyone
involved is undertaking this project as part of their usual
funded employment. This support s jointly funded by
Fundação Osvaldo Cruz, Cochrane Schizophrenia Group,
British Council and CAPES – Coordenação de Aperfeiçoa-
mento de Pessoal de Nível Superior. Drugs to be used in
the trial will be supplied by Secretaria Municipal de Saúde
do Rio de Janeiro.Page 11 of 12
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The success of the TREC-Rio trial depends on active col-
laboration of a large number of people in each of the par-
ticipating hospitals. For this reason, authorship of any
presentations or reports related to the trial will be in the
name of the TREC-Rio Collaborative Group. Inevitably,
for general publication it is not possible to name every-
body that has contributed to a study such as this. Certifi-
cates of collaboration will be provided to those who have
made a substantial contribution but whose name is not
on the final report.
The results will be presented in confidence to the collabo-
rators before publication. Once the final report has been
published, collaborators will have access to the data in the
hospital for additional descriptive analysis. Outcome by
treatment group will not be presented for individual cen-
tres in the main reports of the TREC-Rio trial.
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